The importance of KRAS mutations and EGF 61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer

Annals of Oncology

Volumn 20, Issue 5, 2009, Pages 879-884

  Garm Spindler, Karen Lise ^a   Pallisgaard, N ^a   Rasmussen, A A ^a   Lindebjerg, J ^a   Andersen, R F ^a   Cruger D ^a   Jakobsen, A ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

Author keywords

Cetuximab irinotecan; EGF61A>G; Gene polymorphisms; KRAS; mCRC

Indexed keywords

ADENINE; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GUANINE; GUANINE NUCLEOTIDE BINDING PROTEIN; IRINOTECAN; K RAS PROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFECT; FEMALE; GENE MUTATION; HOMOZYGOTE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PATIENT SELECTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 65549143792     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn712     Document Type: Article

References (30)

1. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351(4): 337-345.
2. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25(13): 1658-1664.
3. Koehne C. Cetuximab plus FOLFIRI first-line in metastatic colorectal cancer (mCRC): The randomized phase III CRYSTAL trial. 9th World Congress on Gastrointestinal Cancer Annual Meeting, Barcelona, Spain, 2007; (Abstr O-0031).
4. Scheithauer W. Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: The EPIC trial Sobrero A. 14th European Cancer Conference, Barcelona, Spain, 2005; 23(9): 1803-1810.
5. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2008; 19(4): 717-723.
6. Hecht JR, Patnaik A, Berlin J et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007; 110(5): 980-988.
7. Benvenuti S, Sartore-Bianchi A, Di NF et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67(6): 2643-2648.
8. De Roock W, Piessevaux H, De Shutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19(3): 508-515.
9. Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96(8): 1166-1169.
10. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25(22): 3230-3237.
11. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26(3): 374-379.
12. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(10): 1626-1634.
13. Bos JL. ras oncogenes in human cancer: A review. Cancer Res 1989; 49(17): 4682-4689.
14. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25(22): 3230-3237.
15. Thebo JS, Senagore AJ, Reinhold DS, Stapleton SR. Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients. Dis Colon Rectum 2000; 43(2): 155-159.
16. Graziano F, Ruzzo A, Loupakis F et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008; 26(9): 1427-1434.
17. Zhang W, Gordon M, Press OA et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 2006; 16(7): 475-483.
18. Shahbazi M, Pravica V, Nasreen N et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002; 359(9304): 397-401.
19. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 2004; 64(4): 1220-1223.
20. Spindler KL, Nielsen JN, Ornskov D et al. Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. Acta Oncol 2007; 46(8): 1113-1117.
21. Spindler KL. The predictive value of EGF A61G gene polymorphism in third-line treatment with cetuximab and irinotecan of patients with metastatic colorectal cancer. ASCO 2008 Gastrointestinal Cancer Symposium, Orlando, FL, 2008. (Abstr 413).
22. Liu W, Innocenti F, Wu MH et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005; 65(1): 46-53.
23. Spindler KL, Lindebjerg J, Nielsen JN et al. Epidermal growth factor receptor analyses in colorectal cancer: A comparison of methods. Int J Oncol 2006; 29(5): 1159-1165.
24. Wang WS, Chen PM, Chiou TJ et al. Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res 2007; 13(12): 3597-3604.
25. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
26. Italiano A, Follana P, Caroli FX et al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008; 15(2): 649-654.
27. Sartore-Bianchi A, Moroni M, Veronese S et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25(22): 3238-3245.
28. Lenz HJ, Van CE, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24(30): 4914-4921.
29. Tajpar S, Peeters M, Humblet H et al. Phase I/II study of cetuximab doseescalation in patients with metastatic colorectal cancer (MCRC) with no or slight skin reaction on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), pharmacodynamics (PD) and efficacy data. J Clin Oncol 2007; 25 (Suppl): 172s (Abstr 4037).
30. Cappuzzo F, Finocchiaro G, Rossi E et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008; 19(4): 717-723.